Jan 8, 2026 12:08PM
Dec 24, 2025 06:00AM
Dec 24, 2025 06:00AM
Aug 12, 2025 04:05PM
Jul 15, 2025 07:45AM
Jul 15, 2025 07:45AM
May 15, 2025 08:45AM SELLAS Life Sciences (SLS) Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
May 15, 2025 08:45AM
May 13, 2025 04:05PM
Apr 8, 2025 08:45AM
Apr 8, 2025 08:45AM
Mar 20, 2025 04:05PM
Jan 8, 2025 08:20AM
Jan 8, 2025 08:20AM SELLAS Announces Key Business Objectives for 2025
Nov 13, 2024 04:15PM
Oct 15, 2024 08:45AM
Oct 15, 2024 08:45AM
Aug 13, 2024 04:10PM
Aug 6, 2024 08:45AM
Aug 6, 2024 08:45AM
Jul 16, 2024 09:05AM SELLAS Life Sciences (SLS) Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
Jul 16, 2024 09:05AM
Jul 8, 2024 08:46AM
Jul 8, 2024 08:45AM
Jun 24, 2024 09:05AM
Jun 24, 2024 09:05AM
Jun 18, 2024 08:45AM
Jun 17, 2024 09:45AM Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
May 1, 2024 08:36AM
May 1, 2024 08:35AM
Mar 28, 2024 04:05PM
Mar 28, 2024 07:00AM
Jan 11, 2024 06:00AM
Jan 9, 2024 08:33AM
Jan 9, 2024 08:30AM SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refra
Jan 3, 2024 07:31AM
Jan 3, 2024 07:30AM
Dec 21, 2023 08:15AM
Dec 21, 2023 08:15AM
Dec 20, 2023 03:48PM
Dec 14, 2023 08:30AM
Nov 29, 2023 08:45AM SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
Nov 13, 2023 08:50AM
Nov 13, 2023 08:50AM
Nov 9, 2023 04:04PM
Oct 30, 2023 09:03AM
Oct 30, 2023 09:03AM
Oct 16, 2023 08:45AM
Oct 16, 2023 08:45AM SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia
Oct 10, 2023 04:16PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All